Ocera Therapeutics, Inc. (NASDAQ:OCRX) shares saw strong trading volume on Friday . 969,372 shares traded hands during trading, a decline of 12% from the previous session’s volume of 1,105,402 shares.The stock last traded at $1.79 and had previously closed at $1.77.

A number of equities research analysts have commented on the company. Zacks Investment Research lowered Ocera Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. HC Wainwright lowered Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price objective for the company. in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $1.69.

Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.24). equities analysts predict that Ocera Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.

A hedge fund recently raised its stake in Ocera Therapeutics stock. Hikari Power Ltd grew its position in shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 79.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 676,596 shares of the biopharmaceutical company’s stock after buying an additional 300,000 shares during the quarter. Hikari Power Ltd owned approximately 2.55% of Ocera Therapeutics worth $771,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 17.69% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/10/ocera-therapeutics-ocrx-sees-large-volume-increase.html.

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.